gsk3326595
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02783300)
Timeline
Indications
Mechanism of action
PRMT5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk3326595
- gsk3326595
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04676516 | Phase 2 | Dec 21, 2020 | GlaxoSmithKline, Hamilton Health Sciences Corporation, Ontario Institute for Cancer Research, University of Ottawa, University of Toronto |
| NCT03614728 | Phase 2 | Oct 15, 2018 | GlaxoSmithKline |
| NCT02783300 | Phase 1 | Aug 1, 2016 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 2 | 2 | 2016 |
| Hamilton Health Sciences Corporation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Ontario Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Ottawa | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1